Cancers of the upper gastro-intestinal tract: A review of somatic mutation distributions

Archives of Iranian Medicine

Volumn 17, Issue 4, 2014, Pages 286-292

  Abedi Ardekani, Behnoush ^a   Hainaut, Pierre ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

Author keywords

Esogastric junction; Mutations; Upper GI tract cancers

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 4, 5 BISPHOSPHATE 3 KINASE; PROTEIN; PROTEIN P53; PROTEIN PATCHED 1; PROTEIN TYROSINE KINASE; PROTEOME; RHOMBOID FAMILY MEMBER 2; TRANSCRIPTION FACTOR NF E2; TRANSCRIPTOME; UNCLASSIFIED DRUG; UVOMORULIN; CELL SURFACE RECEPTOR; NFE2L2 PROTEIN, HUMAN; NOTCH1 PROTEIN, HUMAN; PATCHED RECEPTORS; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; RAS PROTEIN; TRANSCRIPTION FACTOR NRF2;

ALCOHOLISM; ANEUPLOIDY; ARTICLE; CANCER RISK; CARDIA CARCINOMA; CHRONIC GASTRITIS; DIGESTIVE SYSTEM CANCER; DUODENUM CANCER; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS DYSPLASIA; GASTROESOPHAGEAL REFLUX; GENE MUTATION; GENETIC PREDISPOSITION; HELICOBACTER PYLORI; HUMAN; LOWER ESOPHAGUS SPHINCTER; METABOLOME; METAPLASIA; PHYLOGENY; SOMATIC MUTATION; STOMACH CANCER; VATER PAPILLA CARCINOMA; WNT SIGNALING PATHWAY; ADENOCARCINOMA; DUODENUM TUMOR; ESOPHAGUS TUMOR; GENETICS; MUTATION; SQUAMOUS CELL CARCINOMA; STOMACH TUMOR;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DUODENAL NEOPLASMS; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NF-E2-RELATED FACTOR 2; PHOSPHATIDYLINOSITOL 3-KINASES; RAS PROTEINS; RECEPTOR, NOTCH1; RECEPTORS, CELL SURFACE; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899652582     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127: 2893-2917.
2. Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. Semin Oncol. 2004; 31: 450-464.
3. Chandrasoma P. What is adenocarcinoma of the esophagogastric junction? Am J Gastroenterol. 2008; 103: 492-493.
4. Odze RD. Pathology of the gastroesophageal junction. Semin Diagn Pathol. 2005; 22: 256-265.
5. Matsuda A, Machii R. Trends in stomach cancer mortality rates in Japan, USA, UK, France and Korea based on the WHO mortality database. Jpn J Clin Oncol. 2012; 42: 154.
6. Correa P. The biological model of gastric carcinogenesis. IARC Sci Publ. 2004; (157): 301-310.
7. Jankowski JA, Wright NA, Meltzer SJ, Triadafilopoulos G, Geboes K, Casson AG, et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol. 1999; 154: 965-973.
8. Koppert LB, Wijnhoven BP, van Dekken H, Tilanus HW, Dinjens WN. The molecular biology of esophageal adenocarcinoma. J Surg Oncol. 2005; 92: 169-190.
9. Lambert R, Hainaut P. Esophageal cancer: the precursors (Part II). En-doscopy. 2007; 39: 659-664.
10. Lehmann K, Schneider PM. Differences in the molecular biology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res. 2010; 182: 65-72.
11. Lin J, Beerm DG. Molecular biology of upper gastrointestinal malignancies. Semin Oncol. 2004; 31: 476-486.
12. Saikawa Y, Fukuda K, Takahashi T, Nakamura R Takeuchi H, Kitaga-wa Y. Gastric carcinogenesis and the cancer stem cell hypothesis. Gastric Cancer. 2010; 13: 11-24.
13. Sarbia M, Geddert H, Klump B, Kiel S, Iskender E, Gabbert HE. Hypermethylation of tumor suppressor genes (p16INK4A, p14ARF and APC) in adenocarcinomas of the upper gastrointestinal tract. Int J Cancer. 2004; 111: 224-228.
14. Yasui W, Sentani K, Sakamoto N, Anami K, Naito Y, Oue N. Molecular pathology of gastric cancer: research and practice. Pathol Res Pract. 2011; 207: 608-612.
15. Dawsey SM, Lewin KJ. Histologic precursors of squamous esopha-geal cancer. Pathol Annu. 1995; 30 (Pt 1): 209-26.
16. Wang WC, Wu TT, Chandan VS, Lohse CM, Zhang L. Ki-67 and ProExC are useful immunohistochemical markers in esophageal squa-mous intraepithelial neoplasia. Hum Pathol. 2011; 42: 1430-1437.
17. Abedi-Ardekani B, Sotoudeh M, Semnani S, Shakeri R, Taghavi N, Nasrollahzadeh D, et al. Esophagitis may not be a Major Precursor Lesion for Esophageal Squamous Cell Carcinoma in a High Incidence Area in North-Eastern Iran. Middle East J of Dig Dis. 2011; 3: 28-34.
18. Kamangar F, Malekzadeh R, Dawsey SM, Saidi F. Esophageal cancer in Northeastern Iran: a review. Arch Iran Med. 2007; 10: 70-82.
19. Lambert R, Hainaut P. Esophageal cancer: cases and causes (part I). Endoscopy. 2007; 39: 550-555.
20. Gao GF, Roth MJ, Wei WQ, Abnet CC, Chen F, Lu N, et al. No association between HPV infection and the neoplastic progression of esophageal squamous cell carcinoma: result from a cross-sectional study in a high-risk region of China. Int J Cancer. 2006; 119: 1354-1359.
21. Herbster S, Ferraro CT, Koff NK, Rossini A, Kruel CD, Andreollo NA, et al. HPV infection in Brazilian patients with esophageal squa-mous cell carcinoma: interpopulational differences, lack of correlation with surrogate markers and clinicopathological parameters. Cancer Lett. 2012; 326: 52-58.
22. Kamangar F, Qiao YL, Schiller JT, Dawsey SM, Fears T, Sun XD, et al. Human papillomavirus serology and the risk of esophageal and gastric cancers: results from a cohort in a high-risk region in China. Int J Cancer. 2006; 119: 579-584.
23. Patel K, Mining S, Wakhisi J, Gheit T, Tommasino M, Martel-Planche G, et al. TP53 mutations, human papilloma virus DNA and inflammation markers in esophageal squamous cell carcinoma from the Rift Valley, a high-incidence area in Kenya. BMC Res Notes. 2011; 4: 469.
24. Sitas F, Egger S, Urban MI, Taylor PR, Abnet CC, Boffetta P, et al. InterSCOPE study: Associations between esophageal squamous cell carcinoma and human papillomavirus serological markers. J Natl CancerInst. 2012; 104: 147-158.
25. Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer. 2002; 99: 860-868.
26. Islami F, Kamangar F, Nasrollahzadeh D, Moller H, Boffetta P, Male-kzadeh R. Oesophageal cancer in Golestan Province, a high-incidence area in northern Iran-a review. Eur J Cancer. 2009; 45: 3156-3165.
27. Lambert R, Hainaut P. The multidisciplinary management of gastrointestinal cancer. Epidemiology of oesophagogastric cancer. Best Pract Res Clin Gastroenterol. 2007; 21: 921-945.
28. Tran GD, Sun XD, Abnet CC, Fan JH, Dawsey SM, Dong ZW, et al. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer. 2005; 113: 456-463.
29. Dawsey SM, Wang GQ, Taylor PR, Li JY, Blot WJ, Li B, et al. Effects of vitamin/mineral supplementation on the prevalence of histological dysplasia and early cancer of the esophagus and stomach: results from the Dysplasia Trial in Linxian, China. Cancer Epidemiol Biomarkers Preev. 1994; 3: 167-172.
30. Taylor PR, Li B, Dawsey SM, Li JY, Yang CS, Guo W, et al. Prevention of esophageal cancer: the nutrition intervention trials in Linxian, China. Linxian Nutrition Intervention Trials Study Group. Cancer Res. 1994; 54: 2029s-2031s.
31. Lenglinger J, Riegler M, Cosentini E, Asari R, Mesteri I, Wrba F, et al. Review on the annual cancer risk of Barrett's esophagus in persons with symptoms of gastroesophageal reflux disease. Anticancer Res. 2012; 32: 5465-5473.
32. Pohl H, Wrobel K, Bojarski C, Voderholzer W, Sonnenberg A, Rosch T, et al. Risk factors in the development of esophageal adenocarci-noma. Am J Gastroenterol. 2013; 108: 200-207.
33. Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003; 95: 1404-1413.
34. Chandrasoma P, Wickramasinghe K, Ma Y, DeMeester T. Adenocarcinomas of the distal esophagus and gastric cardia are predominantly esophageal carcinomas. Am J Surg Pathol. 2007; 31: 569-575.
35. Taniere P, Martel-Planche G, Maurici D, Lombard-Bohas C, Scoazec JY, Montesano R, et al. Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia. Am J Pathol. 2001; 158: 33-40.
36. Derakhshan MH, Malekzadeh R, Watabe H, Yazdanbod A, Fyfe V, Kazemi A, et al. Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer. Gut 2008; 57: 298-305.
37. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF, Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991; 265: 1287-1289.
38. Devesa SS, Fraumeni JF, Jr. The rising incidence of gastric cardia cancer. JNatl Cancer Inst. 1999; 91: 747-749.
39. Hassan HA, Sharma VK, Raufman JP. Changing trends in gastric carcinoma at a university medical center: a twelve-year retrospective analysis. J Clin Gastroenterol. 2001; 32: 37-40.
40. Vial M, Grande L, Pera M. Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res. 2010; 182: 1-17.
41. Clarke AT, Wirz AA, Seenan JP, Manning JJ, Gillen D, McColl KE. Paradox of gastric cardia: it becomes more acidic following meals while the rest of stomach becomes less acidic. Gut. 2009; 58: 904-909.
42. Correa P. Gastric cancer: overview. Gastroenterol Clin North Am. 2013; 42: 211-217.
43. Correa P, Piazuelo MB. The gastric precancerous cascade. J Dig Dis. 2012; 13: 2-9.
44. Kountouras J, Zavos C, Chatzopoulos D, Katsinelos P. New aspects ofHelicobacter pylori infection involvement in gastric oncogenesis. J Surg Res. 2008; 146: 149-158.
45. Tahara E. Genetic pathways of two types of gastric cancer. IARC Sci Publ. 2004; (157): 327-349.
46. Trajkov D, Stardelova K, Dimitrova M, Mishevski J, Serafimoski V Helicobacter pylori and gastric carcinoma. Prilozi. 2007; 28: 39-46.
47. Risk JM, Field EA, Field JK, Whittaker J, Fryer A, Ellis A, et al. Ty-losis oesophageal cancer mapped. Nat Genet. 1994; 8: 319-321.
48. Blaydon DC, Etheridge SL, Risk JM, Hennies HC, Gay LJ, Carroll R, et al. RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome. Am J Hum Genet. 2012; 90: 340-346.
49. Hemminki K, Sundquist J, Ji J. Familial risk for gastric carcinoma: an updated study from Sweden. Br J Cancer. 2007; 96: 1272-1277.
50. Lindor NM, McMaster ML, Lindor CJ, Greene MH. Concise handbook of familial cancer susceptibility syndromes-second edition. J Natl Cancer Inst Monogr. 2008; (38): 1-93.
51. Hainaut P, Olivier M, Wiman KG. p53 in the Clinics. 1st ed. New York: Springer; 2013.
52. Li VS, Wong CW, Chan TL, Chan AS, Zhao W, Chu KM, et al. Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer. 2005; 5: 29.
53. Hu N, Wang C, Su H, Li WJ, Emmert-Buck MR, Li G, et al. High frequency of CDKN2A alterations in esophageal squamous cell carcinoma from a high-risk Chinese population. Genes Chromosomes Cancer. 2004; 39: 205-216.
54. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004; 304: 554.
55. Loyo M, Li RJ, Bettegowda C, Pickering CR, Frederick MJ, Myers JN, et al. Lessons learned from next-generation sequencing in head and neck cancer. Head Neck. 2013; 35: 454-463.
56. Nguyen BC, Lefort K, Mandinova A, Antonini D, Devgan V, Della Gatta G, et al. Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. Genes Dev. 2006; 20: 1028-1042.
57. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011; 333: 1154-1157.
58. Agrawal N, Jiao Y, Bettegowda C, Hutfless SM, Wang Y, David S, et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov. 2012; 2: 899-905.
59. Wang NJ, Sanborn Z, Arnett KL, Bayston LJ, Liao W, Proby CM, et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A. 2011; 108: 17761--17766.
60. Joshi PS, Deshmukh V, Golgire S. Gorlin-Goltz syndrome. Dent Res J (Isfahan). 2012; 9: 100-106.
61. Lam C, Ou JC, Billingsley EM. PTCH-ing It Together: A Basal Cell Nevus Syndrome Review. Dermatol Surg. 2013; 39: 1557-1572.
62. Yang L, Wang LS, Chen XL, Gatalica Z, Qiu S, Liu Z, et al. Hedgehog signaling activation in the development of squamous cell carcinoma and adenocarcinoma of esophagus. Int J Biochem Mol Biol. 2012; 3: 46-57.
63. Li W, Kong AN. Molecular mechanisms ofNrf2-mediated antioxidant response. Mol Carcinog. 2009; 48: 91-104.
64. Zimmermann S, Peters S. Going beyond EGFR. Ann Oncol. 2012; 23 (suppl 10): x197-x203.
65. Cheng XX, Wang ZC, Chen XY, Sun Y, Kong QY, Liu J, et al. Frequent loss of membranous E-cadherin in gastric cancers: A cross-talk with Wnt in determining the fate of beta-catenin. Clin Exp Metastasis. 2005; 22: 85-93.
66. Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, et al. Exome and whole-genome sequencing of esophageal adenocarci-noma identifies recurrent driver events and mutational complexity. Nat Genet. 2013; 45: 478-486.